EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MEDIPOST Co. Ltd (078160) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of MEDIPOST Co. Ltd KRW 3,576, price KRW 8,970, upside -60.1%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7078160009

MC Thin data Sep 24, 2026

MEDIPOST Co. Ltd

078160 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 3,576 KRW · Strongly overvalued (−60%)
!Quality 24/100
!Expensive Growth (revenue 5y +8.7 %/yr)
!Thin margins · 4.4% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/7)
!Narrow moat 15/100
!Evidence only low, so the estimate is less certain
Watch MEDIPOST Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

30,020 KRW 5,500 KRW Fair Value 3,576 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 5,500 KRW – 30,020 KRW · fair‑value band 2,669 KRW – 5,337 KRW · the 8,970 KRW price screens above the 3,576 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow MEDIPOST Co. in your weekly email

Every Wednesday you see whether MEDIPOST Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases.

Show more

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease. Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand name. MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.

Stock analysis

MEDIPOST Co. Ltd (078160) currently trades at 8,970 KRW, while our model-based Fair Value estimate is 3,576 KRW, implying the stock looks roughly 150.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 2,669 KRW (bear) to 5,337 KRW (bull), the price of 8,970 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

MEDIPOST Co. Ltd reported revenue of 73.7B KRW in FY2025 versus 54.9B KRW in FY2021, a compound +7.6%/yr. Reported net income was −85.4B KRW in FY2025.

Key figures

Market cap 351B KRW (≈ $258M) · P/S ratio 5.49 · Net margin −116% · Return on equity −2,667% · Return on assets (EBIT) −7.4% · Operating margin −26.3% · Revenue (TTM) 62.4B KRW · Revenue growth (YoY) +23.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 68% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −33% fair-value upside, at −60%, 078160 screens richer than that median.

Fair Value models

Bear 2,669 KRW Fair Value 3,576 KRW Bull 5,337 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3,186 KRW 4,269 KRW 6,371 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 3,186 KRW 4,269 KRW 6,371 KRW 54

Open the full fair value analysis →

Notify me when 078160 reaches fair value

Put 078160 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 26 · Market factors (momentum, volatility) 19

Profitability 4
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 72
Disciplined investing over empire-building
Low Volatility 39
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic). Over 10 years: +7.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.0% (2020) → −92.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

078160 screens 151% overvalued. Compare with Bioneer Corporation →

Compare MEDIPOST Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2626 stocks

Beats the sector median on 2/7 measures
Overall it trails its sector peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −60% · Below median
Profitability
Return on assets −3% · Below median
Net margin (TTM) 4% · Below median
Operating margin (TTM) −26% · Bottom 25%
Growth and dividend
Revenue growth 23% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)100 · sector 21
PAST (return on equity)0 · sector 13
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Bioneer Corporation 064550 8,180 KRW 3,547 KRW −57%
Macrogen, Inc 038290 12,090 KRW 4,457 KRW −63%
Cell Biotech Co 049960 14,920 KRW 15,078 KRW +1%
Panagene Inc 046210 1,102 KRW 480.36 KRW −56%
Biotoxtech Co 086040 2,240 KRW 1,916 KRW −14%
Pluri Inc PSTI 3.30 ILA 0.9600 ILA −71%
Eli Lilly and Company LLY $1,182 $792.04 −33%
Johnson & Johnson, JNJ $270.68 $168.85 −38%
AbbVie Inc ABBV $265.12 $259.62 −2%
UnitedHealth Group UNH $375.01 $295.49 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEDIPOST Co. Ltd · Fair Value
3,576 KRW −151%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "MEDIPOST Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/078160

Frequently asked questions

Is MEDIPOST Co. Ltd (078160) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,576 KRW versus a price of 8,970 KRW, about −60% upside (overvalued).
What is the fair value of 078160?
Our model-based fair value for MEDIPOST Co. Ltd is 3,576 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,970 KRW.
What is the quality score of 078160?
MEDIPOST Co. Ltd has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDIPOST Co. Ltd (078160)?
Our model-based price target is the fair value of 3,576 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2,669 KRW, optimistic scenario 5,337 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDIPOST Co. Ltd stock forecast for 2026?
Our models put fair value at 3,576 KRW, about −60% upside versus a price of 8,970 KRW (overvalued). Cautious scenario 2,669 KRW, optimistic scenario 5,337 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEDIPOST Co. Ltd (078160)?
MEDIPOST Co. Ltd reported trailing-twelve-month revenue of about 62.4B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of MEDIPOST Co. Ltd (078160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDIPOST Co. Ltd it is 3,576 KRW per share (as of Sep 24, 2026), against a price of 8,970 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MEDIPOST Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 078160 trades above its calculated fair value: price 8,970 KRW, fair value 3,576 KRW, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 078160?
No. The price is what the market pays today (8,970 KRW); the fair value is what the company's own numbers justify (3,576 KRW). For MEDIPOST Co. Ltd the two are 5,394 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDIPOST Co. Ltd worth?
The market values MEDIPOST Co. Ltd at about 351B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,970 KRW; our models calculate a fair value of 3,576 KRW per share.
What do the bullish and bearish scenarios say about 078160?
Our models span a range for MEDIPOST Co. Ltd: cautious scenario 2,669 KRW, base 3,576 KRW, optimistic 5,337 KRW per share (as of Sep 24, 2026, price 8,970 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEDIPOST Co. Ltd (078160)?
Balance-sheet figures for MEDIPOST Co. Ltd (as of Sep 24, 2026): debt of 0.03 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 078160 from its 52-week high?
MEDIPOST Co. Ltd trades at 8,970 KRW, about 68% below its 52-week high of 28,000 KRW and 19% above the low of 7,520 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,576 KRW is for.
Which stocks are comparable to MEDIPOST Co. Ltd?
From the same area (Healthcare) we also value Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDIPOST Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 8,970 KRW, calculated fair value 3,576 KRW (−60%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 078160 calculated?
We run MEDIPOST Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,576 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. MEDIPOST Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDIPOST Co. Ltd (078160)?
The closing price on Sep 23, 2026 was 8,970 KRW. Our model-based fair value is 3,576 KRW, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDIPOST Co. Ltd right now?
The price sits above even our optimistic bull case (5,337 KRW). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,669 KRW to 5,337 KRW) leaves room in how you read the outcome.

Key figures of MEDIPOST Co. Ltd

How large is the market capitalisation of MEDIPOST Co. Ltd (078160)?
The market capitalisation of MEDIPOST Co. Ltd is 351B KRW (≈ $258M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDIPOST Co. Ltd (078160)?
The price-to-sales ratio of MEDIPOST Co. Ltd is 5.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of MEDIPOST Co. Ltd (078160)?
The net margin of MEDIPOST Co. Ltd is −116% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDIPOST Co. Ltd (078160)?
The return on equity (ROE) of MEDIPOST Co. Ltd is −2,667% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDIPOST Co. Ltd (078160)?
On an EBIT basis the return on assets of MEDIPOST Co. Ltd is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDIPOST Co. Ltd (078160)?
The operating margin of MEDIPOST Co. Ltd is −26.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDIPOST Co. Ltd (078160)?
Revenue at MEDIPOST Co. Ltd is growing +23.4% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDIPOST Co. Ltd (078160)?
Earnings per share at MEDIPOST Co. Ltd are growing +975% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does MEDIPOST Co. Ltd (078160) generate?
The free cash flow of MEDIPOST Co. Ltd is −60.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MEDIPOST Co. Ltd (078160) carry?
The net debt of MEDIPOST Co. Ltd is 32.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MEDIPOST Co. Ltd in the live analysis

One click puts MEDIPOST Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.